The Medicines and Healthcare products Regulatory Agency (MHRA) has launched its new business plan for 2024/25, with a focus on enabling access to innovative healthcare products while ensuring delivery for all who need its services – patients and the public, healthcare professionals, researchers and developers.

MHRA's core mission will remain the same: to protect and promote public health by ensuring that healthcare products, used every day by millions of people in the UK, work and are acceptably safe.

The Business Plan will also reflect developments in regulatory science, which inform the Agency’s plan to create a UK network of Centres of Excellence in Regulatory Science.

The latest plan is build around four strategic priorities: maintain public trust through transparency and proactive communication, including working to address health inequalities; enable healthcare access to safe and effective medical products; deliver scientific and regulatory excellence through strategic partnerships; and become an agency where people flourish alongside a responsive customer service culture.

Dr June Raine, chief executive of the MHRA, said: "To take full advantage of today’s exciting developments in science and technology for the benefit of patients, we will focus on facilitating access to innovative new products while also ensuring continued access to well-established healthcare products that are the backbone of NHS healthcare.

"We will continue to invest in our talented staff by creating satisfying roles and careers, implement an exciting and robust talent management programme, promote diversity and inclusivity and continue to grow as an organisation where every individual can reach their full potential and deliver excellent performance."